Lentivirus-mediated Conditional Gene Expression
- PMID: 34859120
- PMCID: PMC8595424
- DOI: 10.21769/BioProtoc.4205
Lentivirus-mediated Conditional Gene Expression
Abstract
The ability to identify the role of a particular gene within a system is dependent on control of the expression of that gene. In this protocol, we describe a method for stable, conditional expression of Nod-Like receptors (NLRs) in THP-1 cells using a lentiviral expression system. This system combines all the necessary components for tetracycline-inducible gene expression in a single lentivector with constitutive co-expression of a selection marker, which is an efficient means for controlling gene expression using a single viral infection of cells. This is done in a third generation lentiviral expression platform that improves the safety of lentiviruses and allows for greater gene expression than previous lentiviral platforms. The lentiviral expression plasmid is first engineered to contain the gene of interest driven by a TRE (tetracycline response element) promoter in a simple gateway cloning step and is then co-transfected into HEK293T cells, along with packaging and envelope plasmids to generate the virus. The virus is used to infect a cell type of interest at a low MOI so that the majority of the transduced cells contain a single viral integration. Infected cells are grown under selection, and viral integration is validated by qPCR. Gene expression in stably transduced cells is induced with doxycycline and validated by qPCR, immunoblot, and flow cytometry. This flexible lentiviral expression platform may be used for stable and robust induction of a gene of interest in a range of cells for multiple applications. Graphic abstract: Schematic overview of lentiviral transduction of THP-1 cells.
Keywords: Lentivirus; NLR; NOD1; Stable expression; TRE; Tetracycline.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.
Conflict of interest statement
Competing interestsLeah Rommereim is an employee and stockholder of SEngine Precision Medicine. None of the other authors have any competing financial interests.
Figures
References
-
- Barde I., Salmon P. and Trono D.(2010). Production and titration of lentiviral vectors. Curr Protoc Neurosci Chapter 4: Unit 4 21. - PubMed
-
- Connolly J. B.(2002). Lentiviruses in gene therapy clinical research. Gene Ther 9(24): 1730-1734. - PubMed
-
- Kutner R. H., Zhang X. Y. and Reiser J.(2009). Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4(4): 495-505. - PubMed
-
- Li M. J., Kim J., Li S., Zaia J., Yee J. K., Anderson J., Akkina R. and Rossi J. J.(2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12(5): 900-909. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
